Hyperbaric Oxygen for Aging: Reading the Telomere Study Honestly

Written by the Nuvirox Research Team

Short answer: the study is real, the result is striking, and the design cannot support the claims built on it. Hyperbaric oxygen therapy has become a fixture of longevity clinics largely on the strength of one 2020 paper reporting more than 20% telomere lengthening in circulating immune cells. That paper exists and says what it is quoted as saying. It also had 35 participants, no control arm, and measured a biomarker rather than an outcome. Both halves of that sentence deserve equal weight.

Design of the 2020 prospective trial. Note the absence of a control arm — every participant received the intervention, and comparisons were made against their own baseline.

What is hyperbaric oxygen therapy?

Breathing oxygen at above-atmospheric pressure inside a sealed chamber. The pressure allows far more oxygen to dissolve directly into blood plasma than haemoglobin alone could carry, which raises tissue oxygen tension substantially.

It is a well-established, evidence-backed treatment for a specific set of conditions: decompression sickness, carbon monoxide poisoning, certain non-healing wounds, radiation injury to tissue, and some serious infections. None of those indications is in dispute. The longevity application is a separate and much newer proposition.

The theoretical basis is what researchers call the hyperoxic-hypoxic paradox. Repeated intermittent swings between high and normal oxygen appear to trigger some of the same adaptive responses that actual hypoxia produces — including HIF-mediated signalling — without the oxygen deprivation. It is a coherent idea. It also predicts a great deal more than has been demonstrated.

What human studies actually show

The trial that launched the field: 35 adults, 60 daily sessions. Hachmo and colleagues enrolled 35 healthy, independently living adults aged 64 and over, free of cancer, major cardiovascular disease and neurodegenerative disorders. Each received 60 daily hyperbaric exposures over roughly three months. Blood was drawn at baseline, at the 30th and 60th sessions, and one to two weeks after the final session.

The telomere findings were large. Telomere length in T helper, T cytotoxic, natural killer and B cells increased by over 20%. B cells showed the biggest change — increases of about 25.7% at session 30, 29.4% at session 60, and 37.6% post-treatment. Natural killer cell telomeres increased by about 20.6% by session 60. For context, telomere length in adults normally shortens gradually; increases of this magnitude are not what the field expects to see.

Senescent cell populations fell. Senescent T helper cells decreased by about 37.3% post-treatment, and senescent cytotoxic T cells by about 11%. Clearance of senescent cells is one of the central targets of longevity research, which is why this result attracted as much attention as the telomere data.

The honest counterweight: this design cannot establish that the intervention caused anything. There was no control group, no randomisation and no blinding. Every participant knew they were receiving treatment, and every comparison was against their own baseline. Telomere length assays carry meaningful measurement variability, and the reported standard deviations were large relative to the means — the B cell change at the 30th session was 25.68% with a standard deviation of 40.42, meaning individual responses varied enormously and some participants presumably went the other way. The measurement was also made in isolated circulating blood cells, where a shift in the proportion of cell subpopulations could change the average telomere length without any individual cell changing at all. The authors themselves noted that the dose–response relationship remains poorly understood and that further study is needed.

Why does the missing control group matter so much?

Because three months of daily attendance changes far more than oxygen exposure. Participants committed to attending a medical facility five days a week for twelve weeks. That schedule brings routine, transport, social contact, regular clinical monitoring and a strong sense of being cared for. Any of those could plausibly influence immune cell populations.

There is also regression to the mean. Participants were recruited into an aging study; if baseline measurements happened to catch people at a low point, subsequent measurements would drift upward regardless of treatment. A control group receiving sham sessions would separate these possibilities. Without one, the result is a well-documented observation rather than a demonstrated effect.

This is a general pattern in longevity research worth internalising, and it recurs across topics we have covered, from what the NAD+ and aging evidence honestly shows to the way biomarker studies get reported as outcome studies.

What hyperbaric oxygen won’t do

It will not demonstrably extend lifespan or improve function, because neither was measured. The trial reported telomere length and senescence markers. Telomere length is a biomarker whose relationship to health outcomes is genuinely complicated — longer is not uniformly better, and some longer-telomere states associate with increased cancer risk. Treating a biomarker shift as equivalent to rejuvenation is the single most common error in coverage of this study.

Practical considerations also deserve mention. The protocol was 60 daily sessions — a substantial time and financial commitment at longevity clinic rates. Hyperbaric oxygen has real contraindications, including certain lung conditions and untreated pneumothorax, and side effects including barotrauma to the ears and sinuses, temporary visual changes and, at higher exposures, oxygen toxicity. This is a medical procedure with a genuine risk profile, not a spa treatment, and decisions about it belong with a physician.

What would actually settle this?

A randomized, sham-controlled trial with functional endpoints. Sham hyperbaric protocols exist — chambers can be pressurised slightly with normal air, producing the sensory experience without the therapeutic oxygen dose. A trial of that design, powered adequately and measuring things people care about, would resolve the question in either direction.

Until then, the appropriate posture is interest without commitment. The mechanism is plausible, the preliminary signal is unusually large, and the study design cannot distinguish signal from artifact. That is a genuinely open question rather than a settled one — the same category as what we do and don’t know about microplastics, where the measurements are real and the implications are not yet established. For a supplement-side comparison with a similarly interesting mechanism and similarly thin outcome data, see astaxanthin.

Frequently asked questions

Did hyperbaric oxygen reverse aging?

It produced changes in two aging-related biomarkers in an uncontrolled study of 35 people. It did not measure aging, lifespan or function, and no controlled trial has tested whether the biomarker changes correspond to anything meaningful.

Is 60 sessions really necessary?

That is what the protocol used. Interestingly, both telomere and senescence changes peaked at the 30th session in some measures, and the authors acknowledged the optimal protocol has not been determined.

Are the home or soft-shell chambers equivalent?

No. The trial used a medical-grade protocol at therapeutic pressure. Low-pressure soft chambers deliver substantially different oxygen exposure and cannot be assumed to reproduce the same physiology.

Is hyperbaric oxygen safe?

For its established medical indications, with appropriate screening, it has a well-characterised safety profile. It also has real contraindications and side effects, which is why it is administered in medical settings rather than sold over a counter.

Should I try it for longevity?

That is a decision for you and a physician who knows your history. What this article can offer is an accurate description of the evidence: one uncontrolled study, striking biomarker changes, no functional outcomes, no replication under controlled conditions.

From Nuvirox

Why we formulated NAD+ Restore

Our formulation standard is human trial evidence at the dose we use — the same standard by which the hyperbaric telomere study reads as preliminary rather than conclusive. Here is what cleared that bar.

• 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
• 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
• 10 mg galactomannans from fenugreek — to support absorption.
• 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

The hyperbaric longevity story rests on a single uncontrolled trial in 35 people that reported a striking result: over 20% telomere lengthening and a substantial fall in senescent T cells after 60 daily sessions. The paper is real and the numbers are as reported. It also had no control arm, no blinding, wide individual variation, and measured biomarkers in circulating blood cells rather than anything a person would notice. The fair reading is that this is a hypothesis worth testing properly, and that a clinic charging for the protocol is selling considerably more certainty than the literature contains.

References

1. Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY). 2020;12(22):22445–22456. PMID: 33206062. PMCID: PMC7746357. DOI: 10.18632/aging.202188.
2. Nihart AJ, Garcia MA, El Hayek E, et al. Bioaccumulation of microplastics in decedent human brains. Nature Medicine. 2025;31:1114–1119. PMID: 39901044.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.